Vnitr Lek 2016, 62(Suppl 6):102-105

Chronic dysfunction of a transplanted kidney: the problem still unresolved

Ondřej Viklický
Klinika nefrologie, Transplantcentrum IKEM, Praha

Kidney transplantation represents the best treatment of end stage renal diseases in respect of patient survival and quality of life. Despite many advances in immunosuppression and surgical techniques, many kidney grafts are being lost in the long term, mainly due to chronic rejection and recurrence of glomerulonephritis. Calcineurin drug nephrotoxicity, which was overestimated in last decades, seems to have only minor impact on graft survival if any. Despite better understanding of mechanisms of kidney graft injuries, which are reflected by never-ending changes in histological classification systems, optimal treatment strategies are not available for majority of cases. Prospective randomized trials generated from transplant community are therefore warranted to solve many questions about the therapy.

Keywords: chronic rejection; kidney transplantation; nephrotoxicity; recurrence

Received: August 26, 2016; Accepted: October 11, 2016; Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Viklický O. Chronic dysfunction of a transplanted kidney: the problem still unresolved. Vnitr Lek. 2016;62(Supplementum 6):102-105.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44(2): 411-422. Go to original source... Go to PubMed...
    2. Solez K, Colvin RB, Racusen LC et al. Banff '05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 2007; 7(3): 518-526. Go to original source... Go to PubMed...
    3. Haas M, Sis B, Racusen LC et al. Banff meeting report writing committee. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14(2): 272-283. Dostupné z DOI: <http://dx.doi.org/10.1111/ajt.12590>. Go to original source... Go to PubMed...
    4. Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43(6): 1333-1338. Go to original source... Go to PubMed...
    5. Tait BD, Süsal C, Gebel HM et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95(1): 19-47. Dostupné z DOI: <http://dx.doi.org/10.1097/TP.0b013e31827a19cc>. Go to original source... Go to PubMed...
    6. Matl I, Hribova P, Honsova E et al. Potential predictive markers in protocol biopsies for premature renal graft loss. Kidney Blood Press Res 2010; 33(1): 7-14. Dostupné z DOI: <http://dx.doi.org/10.1159/000275705>. Go to original source... Go to PubMed...
    7. Pascual J, Pérez-Sáez MJ, Mir M et al. Chronic renal allograft injury: early detection, accurate diagnosis and management. Transplant Rev (Orlando) 2012; 26(4): 280-290. Dostupné z DOI: <http://dx.doi.org/10.1016/j.trre.2012.07.002>. Go to original source... Go to PubMed...
    8. Eskandary F, Bond G, Regele H et al. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients - Preliminary Results of the Screening Phase of the BORTEJECT Trial. Clin Transpl 2014: 189-195. Go to PubMed...
    9. Canaud G, Delville M, Legendre C. Recurrence of Focal and Segmental Glomerulosclerosis After Transplantation. Transplantation 2016; 100(2): 284-287. Dostupné z DOI: <http://dx.doi.org/10.1097/TP.0000000000000902>. Go to original source... Go to PubMed...
    10. Barbour S, Gill JS. Advances in the understanding of complement mediated glomerular disease: implications for recurrence in the transplant setting. Am J Transplant 2015; 15(2): 312-319. Dostupné z DOI: <http://dx.doi.org/10.1111/ajt.13042>. Go to original source... Go to PubMed...
    11. Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 2011; 11(8): 1645-1649. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1600-6143.2011.03667.x>. Go to original source... Go to PubMed...
    12. Ekberg H, Tedesco-Silva H, Demirbas A et al. [ELITE-Symphony Study]. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357(25): 2562-2575. Go to original source... Go to PubMed...
    13. Schena FP, Pascoe MD, Alberu J et al. [Sirolimus CONVERT Trial Study Group]. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87(2): 233-242. Dostupné z DOI: <http://dx.doi.org/10.1097/TP.0b013e3181927a41>. Go to original source... Go to PubMed...
    14. Liefeldt L, Brakemeier S, Glander P et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12(5): 1192-1198. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1600-6143.2011.03961.x>. Go to original source... Go to PubMed...
    15. Gaston RS, Cecka JM, Kasiske BL et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90(1): 68-74. Dostupné z DOI: <http://dx.doi.org/10.1097/TP.0b013e3181e065de>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.